CytoDyn Return on Equity (ROE) Growth & History (CYDY)
CytoDyn's return on equity was −566.10% for fiscal 2017.
View full CytoDyn company overviewCytoDyn annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2017 | 2017-05-31 | −566.10% | — |
| 2014 | 2014-05-31 | −672.27% | — |
CytoDyn quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q1 2021 | 2020-08-31 | −21,485.71% | — |
| Q4 2017 | 2017-05-31 | −316.65% | −255.96 pp |
| Q3 2017 | 2017-02-28 | −150.32% | −31.54 pp |
| Q2 2017 | 2016-11-30 | −90.54% | — |
| Q1 2017 | 2016-08-31 | −108.09% | — |
| Q4 2016 | 2016-05-31 | −60.69% | — |
| Q3 2016 · Feb 29 | 2016-02-29 | −118.78% | — |
| Q1 2015 | 2014-08-31 | −146.86% | — |
| Q4 2014 | 2014-05-31 | −56.06% | — |
| Q3 2014 | 2014-02-28 | −40.28% | +5136.72 pp |
| Q2 2014 | 2013-11-30 | −79.10% | — |
| Q3 2013 | 2013-02-28 | −5,177.00% | — |
CytoDyn return on equity trends
Between the periods ended 2014-05-31 and 2017-05-31, CytoDyn's return on equity increased from −672.27% to −566.10%, a change of +106.17 percentage points. The latest reported quarter, Q1 2021, shows −21,485.71%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CytoDyn source filings ↗